LLS and Celgene Corporation Announce Partnership to Accelerate Blood Cancer Therapies
For Immediate Release
Contact: Andrea Greif
White Plains, NY (October 3, 2012) - The Leukemia & Lymphoma Society (LLS) and Celgene Corporation today announced a partnership to identify and fund promising blood cancer research projects.
The collaboration will leverage LLS's infrastructure for the identification and acceleration of innovative research at academic centers in priority research areas with significant unmet medical need. These projects will rapidly advance the scientific and medical understanding of the hematological malignances.
Likewise, Celgene and LLS will also work together through LLS's Therapy Acceleration ProgramTM (TAP) to partner with biotechnology companies to speed the development of novel blood cancer treatments.
The Celgene partnership is the first for LLS's new "Targets, Leads & Candidates ProgramTM" a novel approach to venture philanthropy partnerships with the pharmaceutical industry. These partnerships are critical for patients as they have the potential to bring together the most innovative academic science and transform it more quickly with pharmaceutical company resources into critically needed therapies.
"LLS is pleased to be collaborating with Celgene, a company known for innovation in research, to advance both basic academic research in the hematological malignancies, as well as the clinical-development stage projects in our TAP pipeline," said LLS Chief Mission Officer Louis J. DeGennaro, Ph.D. "As always, our goal is getting new therapies to patients more quickly."
"Celgene shares with LLS a deep commitment to high impact treatment for patients with leukemia and lymphoma," said Thomas Daniel, M.D., Celgene President, Research and Early Development. "Through this relationship, we look forward to working with LLS to accelerate delivery of promising therapies to patients."
About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.lls.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.
About Celgene Corporation
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.